Yanfu Sun

491 total citations
15 papers, 367 citations indexed

About

Yanfu Sun is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Yanfu Sun has authored 15 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Hepatology and 5 papers in Surgery. Recurrent topics in Yanfu Sun's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Yanfu Sun is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Yanfu Sun collaborates with scholars based in China and Germany. Yanfu Sun's co-authors include Ruiliang Ge, Gongtian Wei, Lei Yuan, Yi Wang, Lixue Yang, Feng Xue, Hui Xue, Lei Hu, Feng Xue and Feng Shen and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Yanfu Sun

15 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yanfu Sun China	10	152	144	121	106	87	15	367
Gongtian Wei China	8	159 1.0×	132 0.9×	124 1.0×	100 0.9×	75 0.9×	14	329
Yousuke Kuroda Japan	11	249 1.6×	103 0.7×	102 0.8×	149 1.4×	106 1.2×	14	390
Xavier Chopin‐Laly France	10	216 1.4×	87 0.6×	148 1.2×	347 3.3×	66 0.8×	13	498
Juxiang Xiao China	10	107 0.7×	163 1.1×	157 1.3×	275 2.6×	47 0.5×	14	440
Ryusuke Yamaguchi Japan	4	234 1.5×	339 2.4×	127 1.0×	126 1.2×	27 0.3×	5	504
Zili Hu China	12	70 0.5×	135 0.9×	68 0.6×	103 1.0×	76 0.9×	35	316
Renfeng Shan China	12	68 0.4×	90 0.6×	56 0.5×	76 0.7×	122 1.4×	27	297
Burcin Özdirik Germany	12	69 0.5×	105 0.7×	55 0.5×	112 1.1×	56 0.6×	24	319
Jian‐Guo Hong China	11	48 0.3×	85 0.6×	45 0.4×	158 1.5×	52 0.6×	30	315

Countries citing papers authored by Yanfu Sun

Since Specialization

Citations

This map shows the geographic impact of Yanfu Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanfu Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanfu Sun more than expected).

Fields of papers citing papers by Yanfu Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanfu Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanfu Sun. The network helps show where Yanfu Sun may publish in the future.

Co-authorship network of co-authors of Yanfu Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Yanfu Sun. A scholar is included among the top collaborators of Yanfu Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanfu Sun. Yanfu Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Liu, Jianwei, et al.. (2024). Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial. Frontiers in Immunology. 15. 1449211–1449211. 1 indexed citations

Xue, Feng, Jian Zhai, Jianwei Liu, et al.. (2022). Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study.. Journal of Clinical Oncology. 40(16_suppl). e16125–e16125. 2 indexed citations

Zhai, Jian, Jianwei Liu, Zhigang Fu, et al.. (2022). Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study. Journal of Gastrointestinal Oncology. 13(3). 1278–1288. 6 indexed citations

Hu, Lei, et al.. (2022). Prognostic Nomograms Combined Adjuvant Lenvatinib for Hepatitis B Virus–related Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection. Frontiers in Oncology. 12. 919824–919824. 10 indexed citations

Yang, Lixue, Hui Xue, Yanfu Sun, et al.. (2020). CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling. Cell Death and Disease. 11(7). 605–605. 26 indexed citations

Xue, Feng, Lixue Yang, Binghua Dai, et al.. (2020). Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma. PeerJ. 8. e8301–e8301. 13 indexed citations

Dai, Binghua, Liang Qiao, Mingke Zhang, et al.. (2019). lncRNA AK054386 Functions as a ceRNA to Sequester miR-199 and Induce Sustained Endoplasmic Reticulum Stress in Hepatic Reperfusion Injury. Oxidative Medicine and Cellular Longevity. 2019. 1–15. 15 indexed citations

Li, Lei, et al.. (2018). Modulation of VDR and Cell Cycle-Related Proteins by Vitamin D in Normal Pancreatic Cells and Poorly Differentiated Metastatic Pancreatic Cancer Cells. Nutrition and Cancer. 71(5). 818–824. 9 indexed citations

Xue, Feng, Hu Lei, Ruiliang Ge, et al.. (2015). Autophagy-deficiency in hepatic progenitor cells leads to the defects of stemness and enhances susceptibility to neoplastic transformation. Cancer Letters. 371(1). 38–47. 25 indexed citations

10.

Hu, Lei, Feng Xue, Yunyun Li, et al.. (2014). A Long-Term Follow-Up and Comprehensive Observation of Risk and Prognosis Factors of Recurrence and Survival After Resection of Hepatocellular Carcinoma. Cell Biochemistry and Biophysics. 69(3). 421–431. 17 indexed citations

11.

Wang, Yi, et al.. (2014). Survival Outcomes and Prognostic Factors of Surgical Therapy for All Potentially Resectable Intrahepatic Cholangiocarcinoma: a Large Single-Center Cohort Study. Journal of Gastrointestinal Surgery. 18(3). 562–572. 83 indexed citations

12.

Wang, Yi, Heinz‐Otto Peitgen, Andrea Schenk, et al.. (2012). Precise Local Resection for Hepatocellular Carcinoma Based on Tumor-Surrounding Vascular Anatomy Revealed by 3D Analysis. Digestive Surgery. 29(2). 99–106. 18 indexed citations

13.

Yuan, Lei, et al.. (2012). Survival Benefit of Surgical Treatment for Hepatocellular Carcinoma with Inferior Vena Cava/Right Atrium Tumor Thrombus: Results of a Retrospective Cohort Study. Annals of Surgical Oncology. 20(3). 914–922. 111 indexed citations

14.

Li, Li, Yi Wang, Jun Zhang, et al.. (2007). Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications. 358(1). 124–129. 29 indexed citations

15.

Wang, Yi, Han Chen, Mengchao Wu, et al.. (2003). [Surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava].. PubMed. 41(3). 165–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact